Exited portfolio companies
|
ActivX Biosciences, Inc. was acquired by Kyorin Pharmaceutical Co., Ltd. in 2004. |
|||
|
|
|||
|
Arakis Ltd. was acquired by Sosei Co. Ltd. in 2005. |
|||
|
|
|||
|
Arpida Ltd. (ARPN, SWX) is focused on the discovery and development of novel products for the treatment of microbial infections. |
|||
|
|
|||
|
BioImage A/S outlicensed its lead compound to TopoTarget A/S in 2005, and sold its discovery business to Fisher Biosciences in 2006. |
|||
|
|
|||
|
Cabrellis Pharmaceuticals Corp. Cabrellis Pharmaceuticals Corp. was acquired by Pharmion Corporation in 2006. |
|||
|
|
|||
|
CombioA/S was acquired by Arpida Ltd. in 2004. |
|||
|
|
|||
|
Conforma Therapeutics Corp. was acquired by Biogen Idec in 2006. |
|||
|
|
|||
|
Corus Pharma, Inc. was acquired by Gilead Sciences, Inc. in 2006. |
|||
|
|
|||
|
Gloucester Pharmaceuticals was acquired by Celgene Corporation (NASDAQ, CELG) in 2010 |
|||
|
|
|||
|
InSound Medical, Inc. was acquired by Sonova Holding AG in 2010. |
|||
|
|
|||
|
NatImmune A/S was acquired by Azanta A/S in 2009. |
|||
|
|
|||
|
Neurodan A/S was acquired by Otto Bock GmbH Austria in 2005. |
|||
|
|
|||
|
Novexel S.A. was acquired by AstraZeneca in 2010. |
|||
|
|
|||
|
Panacos Pharmaceuticals, Inc. develops small molecule drugs against infectious disease. |
|||
|
|
|||
|
PreciSense A/S PreciSense A/S sold its glucose monitoring assets to Medtronic Inc. in 2009. |
|||
|
|
|||
|
Protein Forest, Inc. was acquired by Cell Bioscience, Inc. in 2009. |
|||
|
|
|||
|
Salmedix, Inc. was acquired by Cephalon, Inc. in 2005. |
|||
|
|
|||
|
Sapphire Therapeutics, Inc. was acquired by Helsinn S.A. in 2009. |
|||
|
|
|||
|
Sosei Co. Ltd. acquired Arakis Ltd. in 2005. |
|||
|
|
|||
|
Thiakis, Ltd. was acquired by Wyeth Pharmaceuticals, Inc. in 2008. |
|||
|
|
|||